Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review
Adverse effects of antibiotics: proportion of participants with one or more serious adverse event · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Cycled inhaled tobramycin (TNS) probably leads to lower adverse effects of antibiotics: proportion of participants with one… compared with culture‐based TNS (moderate certainty).
1 finding from 1 review
Adverse events of treatment · children with cystic fibrosis
1 finding from 1 review
Adverse events during treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (12 or over) and young adults with cystic fibrosis
It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: severe adverse events (total) · children (aged 1 to 12 years) with CF and a newly isolated PA infection
Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).
1 finding from 1 review
Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · children with cystic fibrosis
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review